San Raffaele
| イタリア | トルコ | オーストリア | |
| キイトルーダ療法 | から $22,000 | から $3,300 | から $15,000 |
Bookimedはキイトルーダ療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックでキイトルーダ療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。キイトルーダ療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。キイトルーダ療法の旅路でお一人になることはありません。
The Italian National Health Service (SSN) reimburses Keytruda (pembrolizumab) for specific oncological indications approved by the Italian Medicines Agency (AIFA). Categorized as Class H, the drug is fully covered when administered within hospital settings for conditions like melanoma, lung cancer, and cervical cancer.
Bookimed Expert Insight: While technically a national system, Bookimed data shows regional variations in approval speeds. Centers in Milan, such as San Raffaele, often navigate these protocols efficiently due to their IRCCS accreditation. This status combines clinical care with advanced research, streamlining the administrative process for immunotherapy.
Patient Consensus: Patients emphasize starting paperwork early as authorization can take several weeks. If the initial request is denied, many report successful reimbursement after appealing with more clinical data.
Keytruda (pembrolizumab) is approved in Italy for diverse malignancies following European Medicines Agency (EMA) centralized authorizations. The Italian Medicines Agency (AIFA) regulates national reimbursement for advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and various gastrointestinal, gynecologic, and hematologic cancers.
Bookimed Expert Insight: Italian research centers like San Raffaele in Milan integrate Keytruda into advanced research-driven protocols. While AIFA manages reimbursement, Northern Italian facilities often provide faster diagnostic processing for PD-L1 testing. This logistical speed can significantly accelerate the start of immunotherapy compared to other regions.
Patient Consensus: Patients report that melanoma and lung cancer indications move the fastest through the public system. Early PD-L1 testing is essential to avoid common multi-week delays in starting treatment.
Common side effects of Keytruda (pembrolizumab) include fatigue, skin rashes, and digestive issues. While usually manageable, serious risks involve immune-mediated inflammation where the body attacks healthy organs. Italian research centers like San Raffaele monitor patients closely for pneumonitis, colitis, and thyroid dysfunction during treatment.
Bookimed Expert Insight: Italian IRCCS-accredited hospitals like San Raffaele combine treatment with high-level research. This dual approach helps clinicians catch rare immune-mediated side effects early. Patients benefit from specialized multidisciplinary teams that manage complex endocrine or neurological reactions during long-term immunotherapy cycles.
Keytruda is traditionally administered via a 30-minute intravenous infusion into a vein every 3 or 6 weeks. A new subcutaneous injection now allows administration in only 2 to 5 minutes. This version delivers the medication just under the skin of the thigh or abdomen.
Bookimed Expert Insight: Italian research centers like San Raffaele often lead in adopting these faster delivery methods. While the subcutaneous option saves time, regional public health availability across Italy fluctuates. Choosing private oncology care in Milan may ensure immediate access to 5-minute injection sessions.
Patient Consensus: Patients report that subcutaneous injections significantly improve comfort by preventing vein fatigue. Many recommend tracking thyroid levels early as immune side effects remain identical between both methods.
Patients access Keytruda in Italy through the Servizio Sanitario Nazionale (SSN) or private oncology centers. The Italian Medicines Agency (AIFA) regulates eligibility based on clinical indications. Access requires an oncologist prescription, biomarker testing like PD-L1 expression, and administration at certified hospitals or research institutes.
Bookimed Expert Insight: Italian research hospitals like San Raffaele combine clinical care with extensive research activity. This dual status often grants patients access to newer immunotherapy protocols earlier than standard clinics. Focus on centers with IRCCS accreditation to ensure the most current oncology standards.
Patient Consensus: Patients report that private clinics provide much faster access, usually within 2 to 4 weeks. Most emphasize bringing complete genetic and imaging reports to the first visit to prevent significant delays.
Keytruda (pembrolizumab) shows a wide range of response rates, generally averaging 33.8% across various cancers. Effectiveness depends heavily on PD-L1 expression and genetic indicators like MSI-H. Reported outcomes vary from 11% in gastric cancer to over 80% in specific Hodgkin lymphoma cases.
Bookimed Expert Insight: Italian research centers like San Raffaele in Milan manage massive volumes, serving 300,000 patients annually. This scale is vital for immunotherapy because high-volume centers often possess more granular data on PD-L1 testing. Choosing these experienced hubs ensures more accurate response predictions based on your specific biomarker profile.
Patient Consensus: Many patients emphasize that initial scans at 8–12 weeks might show no change. They suggest viewing stable disease as a significant clinical victory even without a full response.
Italy offers several accelerated access routes for Keytruda, primarily through the Italian Medicines Agency (AIFA) framework. Patients access these therapies via the Law 648/96 list, compassionate use programs, or the AIFA National Fund. These pathways ensure treatment for patients with urgent medical needs before full national reimbursement.
Bookimed Expert Insight: Northern Italian medical centers like San Raffaele often process early access requests faster due to local regional funding. The IRCCS accreditation at these research hospitals combines clinical care with active immunotherapy trials. Patients should target these research-heavy facilities first to increase their chances of securing early access status.
Patient Consensus: Many patients recommend bringing printed AIFA guidelines to initial consultations to clarify eligibility for compassionate use. Local support groups suggest budgeting for one private dose while waiting for regional reimbursement paperwork processing.